Compartilhar
Informação da revista
Vol. 46. Núm. S4.
HEMO 2024
Páginas S573-S574 (outubro 2024)
Vol. 46. Núm. S4.
HEMO 2024
Páginas S573-S574 (outubro 2024)
Acesso de texto completo
EFFICACY AND SAFETY OF VALOCTOCOGENE ROXAPARVOVEC 4 YEARS AFTER GENE TRANSFER IN GENER8-1
Visitas
374
MC Ozeloa, AD Leavittb, J Mahlanguc, G Kenetd, SW Pipee, S Chouf, R Klamrothg,h, F Peyvandii,j, T Robinsonk, GT Groupl
a Centro de Hematologia e Hemoterapia (Hemocentro), Department of Internal Medicine Faculdade de Ciências Médicas (FCM), Universidade Estadual de Campinas (UNICAMP), Campinas, SP, Brazil
b Adult Hemophilia Treatment Center, University of California San Francisco, San Francisco, CA, USA
c Hemophilia Comprehensive Care Center, Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand and NHLS, Johannesburg, South Africa
d The National Hemophilia Center and Amalia Biron Research Institute of Thrombosis and Hemostasis, Sheba Medical Center, Tel Hashomer, Tel Aviv University, Tel Aviv, Israel
e Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor, MI, USA
f Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
g Vascular Medicine and Haemostaseology, Vivantes Klinikum im Friedrichshain, Berlin, Germany
h Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Medical Faculty, University of Bonn, Bonn, Germany
i Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milan, Italy
j Università degli Studi di Milano, Department of Pathophysiology and Transplantation, Milan, Italy
k BioMarin Pharmaceutical Inc., Novato, CA, USA
l GENEr8-1 Trial Group
Ver más
Este item recebeu
Informação do artigo
Resume
Texto Completo
Baixar PDF
Estatísticas
Suplemento especial
Este artigo faz parte de:
Vol. 46. Núm S4

HEMO 2024

Mais dados
Objectives

Valoctocogene roxaparvovec (AAV5-hFVIII-SQ), a gene transfer therapy for severe hemophilia A, enables endogenous factor VIII (FVIII) production to prevent bleeding. We present efficacy and safety outcomes 4-years post-valoctocogene roxaparvovec treatment in the GENEr8-1 trial.

Material and methods

In the open-label, multicenter, phase 3 GENEr8-1 trial (NCT03370913), 134 adult men with severe hemophilia A (FVIII ≤1 IU/dL) without FVIII inhibitors received 6E13 vg/kg valoctocogene roxaparvovec (Intention-To-Treat [ITT] population). Bleeds and FVIII use were self-reported after regular prophylaxis cessation (scheduled Week [W]4). The rollover population, which included 112 HIV-negative participants who enrolled from a non-interventional study, was used for comparisons with baseline FVIII use and bleeding rate. Chromogenic (CSA) and One-Stage Assay (OSA) FVIII activity were assessed in 132 HIV-negative participants (modified ITT [mITT] population). Safety was assessed in the ITT population.

Results

In the ITT population, 118/134 participants completed W208; 24/134 participants resumed prophylaxis. In the rollover population, mean annualized treated bleeding rate was 0.8 bleeds/y, mean annualized bleeding rate for all bleeds was 1.3 bleeds/y, and mean annualized FVIII infusion rate was 6.1 infusions/y over 4-years. During year 4, 81/110 (73.6%) participants had 0 treated bleeds and 68/110 (61.8%) participants had 0 bleeds regardless of treatment. At W208, mean CSA and OSA FVIII activity were 16.1 and 27.1 IU/dL in the mITT population respectively. At W260, mean CSA and OSA FVIII activity were 18.0 and 25.5 IU/dL for the mITT subgroup dosed ≥ 5-years prior. FVIII activity (CSA) ≥ 40, ≥ 5 to < 40, ≥ 3 to < 5, and < 3 IU/dL was verified in 10/130 (7.7%), 68/130 (52.3%), 18/130 (13.8%), and 34/130 (26.2%) of participants, respectively. During year 4, the most common adverse event was alanine aminotransferase (ALT) elevation (56/131 participants; ALT > upper limit of normal or ≥ 1.5× baseline); no participants initiated immunosuppressants for ALT elevation.

Conclusions

At four years post valoctocogene roxaparvovec therapy, bleed control and FVIII expression were maintained in the majority of patients. No new safety signals emerged.

Texto Completo

Conflict of Interest: Prof Margareth C Ozelo has served as an investigator for BioMarin Pharmaceutical Inc. Funding: BioMarin Pharmaceutical Inc has funded the study.

Baixar PDF
Idiomas
Hematology, Transfusion and Cell Therapy
Opções de artigo
Ferramentas